Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Myeloproliferative Disorders 1Leukemia, Biphenotypic, Acute 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

venetoclax 91Azacitidine 75Cytarabine 68Specimen Handling 45fludarabine 44Biopsy 32Cyclophosphamide 29Daunorubicin 27fludarabine phosphate 25Injections 25Decitabine 25Idarubicin 24Busulfan 20Granulocyte Colony-Stimulating Factor 19Whole-Body Irradiation 18Mycophenolic Acid 18Tacrolimus 17Melphalan 17decitabine and cedazuridine drug combination 16gilteritinib 14Stem Cell Transplantation 14CPX-351 14Mitoxantrone 13Peripheral Blood Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Filgrastim 11Etoposide 11Cladribine 11ivosidenib 10revumenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Razoxane × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡